Deleterious PALB2 Gene Mutation
specificA change in the nucleotide sequence of the PALB2 gene that is associated with increased risk of disease.
9
Centers
11
Active Trials
—
Cancer Funding
Top Centers for Deleterious PALB2 Gene Mutation(9)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive High-Volume Research Center | 73.1 |
| 2 | Boston University Cancer CenterBoston, MA High-Volume Research Center | 73.1 |
| 3 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 50.6 |
| 4 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive Active Research Program | 50.6 |
| 5 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 50.6 |
| 6 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program | 50.6 |
| 7 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 50.6 |
| 8 | University of Illinois Cancer CenterChicago, IL Active Research Program | 50.6 |
| 9 | Cancer Center at IllinoisUrbana, IL Active Research Program | 50.6 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →